Who
Carole Ho
Director
Company insider
Files Form 4 as: Director, Royalty Pharma; Chief Medical Officer, Denali Therapeutics; Director, Beam Therapeutics; Director, Ngm Biopharmaceuticals.
In numbers
- Trades disclosed
- 227
- Buys
- 0
- Sells
- 74
- Bought
- $0
- Sold
- $13.2M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 26 Feb 2018
- Last trade
- 5 Jun 2026
- Last filed
- 8 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 8 Jun 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | —4,545 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | —4,545 at $0.00 | filing |
| 13 Aug 2025filed 14 Aug 2025 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Sold | $12K806 at $14.64 | filing |
| 12 Aug 2025filed 14 Aug 2025 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Sold | $40K2,937 at $13.58 | filing |
| 5 Aug 2025filed 7 Aug 2025 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —44,655 at $0.00 | filing |
| 5 Aug 2025filed 7 Aug 2025 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code M | $30K44,655 at $0.68 | filing |
| 31 Jul 2025filed 31 Jul 2025 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | —2,752 at $0.00 | filing |
| 31 Jul 2025filed 31 Jul 2025 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | —5,806 at $0.00 | filing |
| 4 Jun 2025filed 6 Jun 2025 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —33,662 at $0.00 | filing |
| 7 Jan 2025filed 8 Jan 2025 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Sold | $60K2,907 at $20.81 | filing |
| 6 Jan 2025filed 8 Jan 2025 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Sold | $248K12,255 at $20.22 | filing |
| 3 Jan 2025filed 7 Jan 2025 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —162,540 at $0.00 | filing |
| 3 Jan 2025filed 7 Jan 2025 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code A | —54,180 at $0.00 | filing |
| 25 Nov 2024filed 27 Nov 2024 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,845 at $0.00 | filing |
| 25 Nov 2024filed 27 Nov 2024 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code M | $12K17,845 at $0.68 | filing |
| 21 Aug 2024filed 22 Aug 2024 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Sold | $344K14,098 at $24.41 | filing |
| 21 Aug 2024filed 22 Aug 2024 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Sold | $147K5,907 at $24.96 | filing |
| 20 Aug 2024filed 22 Aug 2024 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Sold | $58K2,453 at $23.79 | filing |
| 13 Aug 2024filed 15 Aug 2024 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Sold | $53K2,337 at $22.89 | filing |
| 5 Jun 2024filed 7 Jun 2024 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —23,114 at $0.00 | filing |
News
Denali Therapeutics (NASDAQ:DNLI) vs. Century Therapeutics (NASDAQ:IPSC) Head-To-Head ContrastDNLI · themarketsdaily.com · 19 Oct 2026Denali Therapeutics (NASDAQ:DNLI) and Absci (NASDAQ:ABSI) Head to Head ComparisonDNLI · tickerreport.com · 11 Oct 2026
0 headlines in the last 90 days name Carole Ho; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.